Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Emapticap pegol,Pembrolizumab,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : TME Pharma
Deal Size : Undisclosed
Deal Type : Financing
Details : As NOXXON advances its pipeline with upcoming start of clinical trials this additional liquidity will focus on manufacturing of NOX-A12 clinical trial supply in anticipation of upcoming clinical trials.
Brand Name : NOX-A12
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 01, 2021
Lead Product(s) : Emapticap pegol,Pembrolizumab,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : TME Pharma
Deal Size : Undisclosed
Deal Type : Financing
LOOKING FOR A SUPPLIER?